Loading
TB
Turnstone Biologics Corp. Stock: price and insider trades · United States
Turnstone Biologics Corp.: what insiders have been doing
Turnstone Biologics Corp. has a thin disclosure history in our data (latest filing: 12 August 2025). New filings will appear here as soon as they are published. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
9
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
Revenue17.2M
Net income-63.2M-366.9% margin
Last declaration on 12 August 2025
Declarations9 total
3,099,265 sharesCommon StockSEC:0000947871-25-000748:0
2,726,322 sharesCommon StockSEC:0000950170-25-107403:0
3,099,265 sharesCommon StockSEC:0001415889-25-021337:0
274,990 sharesCommon StockSEC:0001415889-25-021338:0
2,528,864 sharesCommon StockSEC:0001209191-23-043525:0
2,528,864 sharesCommon StockSEC:0001209191-23-043527:0
2,682,599 sharesCommon StockSEC:0000947871-23-000777:0
2,682,599 sharesCommon StockSEC:0000947871-23-000778:0
9 of 9 declarations
About Turnstone Biologics Corp.
Turnstone Biologics Corp. is a biopharmaceutical company focused on developing immunotherapies for cancer treatment. It is listed on NASDAQ under the ticker XNAS.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
